ViferaXS is pioneering the forefront of immunotherapy with its revolutionary T cell activator platform, designed to harness the power of T cells in combating malignant diseases. By focusing on immunopeptidome-derived tumour antigens and employing an innovative adjuvant/formulation, XS15, the platform ensures precise targeting of naturally presented tumour antigens, enabling the direct killing of cancerous cells while activating and recruiting other immune components for a comprehensive response.
We are interested in partnerships and funding discussions.
Company Details
- Employees
- 2
- Founded
- 2022
- Address
- Karlstraße 3, C/o Neckar Hub,germany
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.viferaXS.com
- Keywords
- Oncology, Hematology, Peptide, Cancer Vaccine, Clinical Stage, Immuno-oncology, CLL, AML, Prostate Cancer, F, Fibrolamellar Carcinoma, Rare Disease.
- HQ
- Tübingen, Baden-Württemberg
Viferaxs Questions
Viferaxs's website is http://www.viferaXS.com
Viferaxs's LinkedIn profile is https://de.linkedin.com/company/viferaxs
Viferaxs has
2 employees.
View email and phone details for 2
employees at Viferaxs.
Viferaxs's industry is
Biotechnology Research
Viferaxs's top competitors are
The Länd,
Infrafon,
Senara Gmbh,
Heparegenix Gmbh,
Immatics,
Aimino Tech - Smartreply Ai,
Mira Vision,
Validaitor,
Univents Gmbh,
Moonlight Ai.
Viferaxs's categories are Biotechnology Research
Viferaxs's founding year is 2022
